Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3779287 | 0.91 | EGLN1 (0.45) | EGLN1NR4A2CYP2C9DGAT1 | |
| SCHEMBL3785532 | 0.85 | EGLN1 (0.45) | EGLN1NR4A2CYP2C9DGAT1 | |
| SCHEMBL3774423 | 0.83 | NR4A2 (0.42) | EGLN1NR4A2CYP2C9 | |
| SCHEMBL3774136 | 0.82 | EGLN1 (0.52) | EGLN1NR4A2CYP2C9DGAT1SMN1; SMN2 | |
| SCHEMBL3367431 | 0.82 | EGLN1 (0.61) | EGLN1NR4A2CYP2C9DGAT1NPC1 | |
| SCHEMBL1734914 | 0.82 | CYP2C9 (0.44) | EGLN1NR4A2CYP2C9MEN1KMT2A | |
| SCHEMBL1733791 | 0.81 | CYP2C9 (0.43) | EGLN1NR4A2CYP2C9DGAT1MEN1 | |
| SCHEMBL1733156 | 0.80 | EGLN1 (0.43) | EGLN1NR4A2CYP2C9MEN1KMT2A | |
| SCHEMBL1733991 | 0.79 | NR4A2 (0.55) | EGLN1NR4A2CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL3777768 | 0.79 | EGLN1 (0.54) | EGLN1NR4A2CYP2C9DGAT1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225240-B1 | Derivatives of 6-heterocyclic-imidazo[1,2-a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof | SANOFI SA (FR) | 2014-01-22 | — | — | EP | claimed |
| US-8314109-B2 | 6-heterocyclic-imidazo[1,2-α]pyridine-2-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2012-11-20 | — | — | US | claimed |
| US-20100317675-A1 | 6-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | claimed |
| US-8691990-B2 | 6-heterocyclic imidazo[1,2-α]pyridine-2-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2014-04-08 | — | — | US | disclosed |
| EP-2225240-B1 | Derivatives of 6-heterocyclic-imidazo[1,2-a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof | SANOFI SA (FR) | 2014-01-22 | — | — | EP | disclosed |
| US-20130041152-A1 | 6-HETEROCYCLIC IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | PEYRONEL JEAN-FRANCOIS (FR) | 2013-02-14 | — | — | US | disclosed |
| US-8314109-B2 | 6-heterocyclic-imidazo[1,2-α]pyridine-2-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2012-11-20 | — | — | US | disclosed |
| US-20100317675-A1 | 6-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130041152-A1 | 6-HETEROCYCLIC IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | XDH, REN, IDH2 | EGLN1 1986/4885NR4A2 2105/4885CYP2C9 209/4885 |
| US-20100317675-A1 | 6-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | REN, IDH2, GLS | EGLN1 1845/4885NR4A2 1987/4885CYP2C9 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.